These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Secondary malignancies after bone marrow transplantation in adults. Lowsky R; Lipton J; Fyles G; Minden M; Meharchand J; Tejpar I; Atkins H; Sutcliffe S; Messner H J Clin Oncol; 1994 Oct; 12(10):2187-92. PubMed ID: 7931488 [TBL] [Abstract][Full Text] [Related]
4. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. Baker KS; DeFor TE; Burns LJ; Ramsay NK; Neglia JP; Robison LL J Clin Oncol; 2003 Apr; 21(7):1352-8. PubMed ID: 12663726 [TBL] [Abstract][Full Text] [Related]
5. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S; Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985 [TBL] [Abstract][Full Text] [Related]
6. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients. Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821 [TBL] [Abstract][Full Text] [Related]
7. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Dann EJ; Daugherty CK; Larson RA Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751 [TBL] [Abstract][Full Text] [Related]
8. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Alexander FE; Jarrett RF; Lawrence D; Armstrong AA; Freeland J; Gokhale DA; Kane E; Taylor GM; Wright DH; Cartwright RA Br J Cancer; 2000 Mar; 82(5):1117-21. PubMed ID: 10737396 [TBL] [Abstract][Full Text] [Related]
9. Malignant neoplasms following bone marrow transplantation. Bhatia S; Ramsay NK; Steinbuch M; Dusenbery KE; Shapiro RS; Weisdorf DJ; Robison LL; Miller JS; Neglia JP Blood; 1996 May; 87(9):3633-9. PubMed ID: 8611687 [TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation. Chiang KY; Hazlett LJ; Godder KT; Abhyankar SH; Christiansen NP; van Rhee F; Lee CG; Bridges K; Parrish RS; Henslee-Downey PJ Bone Marrow Transplant; 2001 Dec; 28(12):1117-23. PubMed ID: 11803352 [TBL] [Abstract][Full Text] [Related]
11. Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation. Lynch BA; Vasef MA; Comito M; Gilman AL; Lee N; Ritchie J; Rumelhart S; Holida M; Goldman F Bone Marrow Transplant; 2003 Sep; 32(5):527-33. PubMed ID: 12942101 [TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus in Hodgkin's disease patients in Japan. Tomita Y; Ohsawa M; Kanno H; Hashimoto M; Ohnishi A; Nakanishi H; Aozasa K Cancer; 1996 Jan; 77(1):186-92. PubMed ID: 8630928 [TBL] [Abstract][Full Text] [Related]
13. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center]. Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748 [TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr Virus and HLA-DPB1-*0301 in young adult Hodgkin's disease: evidence for inherited susceptibility to Epstein-Barr Virus in cases that are EBV(+ve). Alexander FE; Jarrett RF; Cartwright RA; Armstrong AA; Gokhale DA; Kane E; Gray D; Lawrence DJ; Taylor GM Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):705-9. PubMed ID: 11401923 [TBL] [Abstract][Full Text] [Related]
15. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Micallef IN; Chhanabhai M; Gascoyne RD; Shepherd JD; Fung HC; Nantel SH; Toze CL; Klingemann HG; Sutherland HJ; Hogge DE; Nevill TJ; Le A; Barnett MJ Bone Marrow Transplant; 1998 Nov; 22(10):981-7. PubMed ID: 9849695 [TBL] [Abstract][Full Text] [Related]
16. Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies. Stamatović D; Balint B; Tukić L; Elez M; Tarabar O; Todorović M; Ostojić G; Tatomirovic Z; Ljubenov M; Marjanović S; Malesević M Vojnosanit Pregl; 2011 Dec; 68(12):1026-32. PubMed ID: 22352263 [TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus expression in Hodgkin's disease in Jordan. Almasri NM; Khalidi HS Saudi Med J; 2004 Jun; 25(6):770-5. PubMed ID: 15195209 [TBL] [Abstract][Full Text] [Related]
18. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361 [TBL] [Abstract][Full Text] [Related]
20. Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients. Liu D; Tammik C; Zou JZ; Ernberg I; Masucci MG; Ringden O; Levitsky V Clin Transplant; 2004 Oct; 18(5):518-24. PubMed ID: 15344953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]